| Juan Cordero, MD | |
|
505 Dutchmans Ln Ste A3, Easton, MD 21601-4302 | |
| (410) 822-2440 | |
| (410) 822-2441 |
| Full Name | Juan Cordero |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 29 Years |
| Location | 505 Dutchmans Ln Ste A3, Easton, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740224245 | NPI | - | NPPES |
| 986800300 | Medicaid | MD | |
| AT540006 | Other | MD | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | D57950 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Anne Arundel Medical Center | Annapolis, MD | Hospital |
| University Of Md Shore Medical Ctr At Chestertown | Chestertown, MD | Hospital |
| Umd Shore Medical Center At Easton | Easton, MD | Hospital |
| Kadlec Regional Medical Center | Richland, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Luminis Health Medical Group, Llc | 2860447315 | 431 |
| Luminis Health Medical Group, Llc | 2860447315 | 431 |
News Archive
MagnaChip Semiconductor Corporation, a Korea-based designer and manufacturer of analog and mixed-signal semiconductor products, today announced it has launched a research collaboration focused on developing innovative, cost-effective silicon magnetic bio-sensor technology capable of monitoring extremely rare cells in blood.
A new blood test called the Tick-Borne Disease Serochip (TBD Serochip) promises to revolutionize the diagnosis of tick-borne disease by offering a single test to identify and distinguish between Borrelia burgdorferi, the pathogen responsible for Lyme disease, and seven other tick-borne pathogens.
Delcath Systems, Inc. announced today that it intends, subject to market and other conditions, to offer up to 8.5 million shares of its common stock in a registered public offering pursuant to its existing shelf registration statement under the Securities Act of 1933. Delcath also intends to grant the underwriters of the offering an option to purchase up to 15% of additional shares of primary stock to cover over-allotments.
ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.
› Verified 3 days ago
| Entity Name | Luminis Health Medical Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073580205 PECOS PAC ID: 2860447315 Enrollment ID: O20050317000146 |
News Archive
MagnaChip Semiconductor Corporation, a Korea-based designer and manufacturer of analog and mixed-signal semiconductor products, today announced it has launched a research collaboration focused on developing innovative, cost-effective silicon magnetic bio-sensor technology capable of monitoring extremely rare cells in blood.
A new blood test called the Tick-Borne Disease Serochip (TBD Serochip) promises to revolutionize the diagnosis of tick-borne disease by offering a single test to identify and distinguish between Borrelia burgdorferi, the pathogen responsible for Lyme disease, and seven other tick-borne pathogens.
Delcath Systems, Inc. announced today that it intends, subject to market and other conditions, to offer up to 8.5 million shares of its common stock in a registered public offering pursuant to its existing shelf registration statement under the Securities Act of 1933. Delcath also intends to grant the underwriters of the offering an option to purchase up to 15% of additional shares of primary stock to cover over-allotments.
ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Juan Cordero, MD 2001 Medical Pkwy, Medical Staff Office, Annapolis, MD 21401-8943 Ph: () - | Juan Cordero, MD 505 Dutchmans Ln Ste A3, Easton, MD 21601-4302 Ph: (410) 822-2440 |
News Archive
MagnaChip Semiconductor Corporation, a Korea-based designer and manufacturer of analog and mixed-signal semiconductor products, today announced it has launched a research collaboration focused on developing innovative, cost-effective silicon magnetic bio-sensor technology capable of monitoring extremely rare cells in blood.
A new blood test called the Tick-Borne Disease Serochip (TBD Serochip) promises to revolutionize the diagnosis of tick-borne disease by offering a single test to identify and distinguish between Borrelia burgdorferi, the pathogen responsible for Lyme disease, and seven other tick-borne pathogens.
Delcath Systems, Inc. announced today that it intends, subject to market and other conditions, to offer up to 8.5 million shares of its common stock in a registered public offering pursuant to its existing shelf registration statement under the Securities Act of 1933. Delcath also intends to grant the underwriters of the offering an option to purchase up to 15% of additional shares of primary stock to cover over-allotments.
ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.
› Verified 3 days ago
Anish M. Hinduja, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5 Martin Court, Easton, MD 21601 Phone: 410-820-9823 Fax: 866-606-6428 | |
Dr. Roshan Bisural, Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 219 S Washington St, Easton, MD 21601 Phone: 410-822-1000 | |
Dr. Michael Patrick Moran, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 556 Cynwood Drive, Suite A, Easton, MD 21601 Phone: 410-221-1185 Fax: 410-221-1187 | |
Dr. Carolyn R Helmly, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 508 Idlewild Ave, Easton, MD 21601 Phone: 410-822-9133 Fax: 410-822-9513 | |
Elizabeth Smelter Clayton, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 505 Dutchmans Ln, Suite A2, Easton, MD 21601 Phone: 410-819-6545 Fax: 410-819-6750 | |
Pratibha Phuyal, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 219 S Washington St, Easton, MD 21601 Phone: 410-822-1000 | |
Robert Bruce Helmly, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 500 Cadmus Ln Ste 207, Easton, MD 21601 Phone: 410-822-5571 Fax: 410-822-3859 |